UMBILICAL CORD PRODUCTS
Disclosed herein, in certain instances, are tissue grafts derived from UCAM. Further disclosed herein, in certain instances, are use for tissue grafts derived from UCAM.
1 - 20 . (canceled)
21 . A composition, comprising: an isolated UCAM that does not comprise a vein or an artery, a cell with metabolic activity, active HIV-1, active HIV-2, active HTLV-1, active hepatitis B, active hepatitis C, active West Nile Virus, active cytomegalovirus, active human transmissible spongiform encephalopathy, or active Treponema pallidum , wherein the natural structural integrity of the isolated UCAM is substantially preserved for at least 15 days after initial procurement.
22 . The composition of claim 21 , wherein the composition has higher yield strength, higher stiffness, higher pull strength, higher tensile strength, and higher suture pull-out strength than a composition comprising placental amniotic membrane (PAM).
23 . The composition of claim 21 , wherein the natural biological activity of the isolated UCAM is substantially preserved for at least 15 days after initial procurement.
24 . The composition of claim 21 , wherein the composition is anti-inflammatory, anti-scarring, anti-angiogenic, anti-adhesion, or promotes wound healing when contacted with an exogenous living cell.
25 . The composition of claim 21 , wherein substantially all red blood cells have been removed from the UCAM.
26 . The composition of claim 21 , wherein the composition is cryopreserved, lyophilized, terminally sterilized, or a combination thereof.
27 . The composition of claim 21 , wherein the composition is substantially-flattened sheet.
28 . The composition of claim 21 , wherein the composition is a tubular sheet.
29 . The composition of claim 21 , wherein the composition is a pulverized powder or a homogenate.
30 . A method of producing a UCAM product, comprising: obtaining pre-frozen umbilical cord, and separating the UCAM from the umbilical vein and umbilical arteries and at least a portion of the Wharton's Jelly, wherein the natural structural integrity of the UCAM product is substantially preserved for at least 15 days after initial procurement.
31 . The method of claim 30 , wherein the natural biological activity of the isolated UCAM is substantially preserved for at least 15 days after initial procurement.
32 . The method of claim 30 , wherein the umbilical cord is obtained from a human, non-primate human, cow or pig.
33 . The method of claim 30 , wherein the UCAM product is anti-inflammatory, anti-scarring, anti-angiogenic, anti-adhesion, or promotes wound healing when contacted with an exogenous living cell.
34 . The method of claim 30 , wherein the UCAM product has higher yield strength, higher stiffness, higher pull strength, higher tensile strength, and higher suture pull-out strength than a composition comprising placental amniotic membrane (PAM).
35 . The method of claim 30 , wherein the UCAM is separated from the umbilical vein and umbilical arteries and at least a portion of the Wharton's Jelly by use of a surgical dermatome.
36 . The method of claim 30 , further comprising inhibiting the metabolic activity of substantially all cells found on the UCAM by freezing or drying the umbilical cord.
37 . The method of claim 30 , further comprising draining blood from the umbilical cord before removing Wharton's Jelly, the umbilical vein, and the umbilical arteries.
38 . The method of claim 30 , further comprising removing substantially all red blood cells from the UCAM.
39 . The method of claim 30 , further comprising lyophilizing, cryopreserving, pulverizing, or terminally sterilizing the UCAM product.
40 . A method of promoting wound healing and reducing inflammation, scarring, angiogenesis, and adhesion in a plurality of exogenous cells in an individual in need thereof, comprising: providing to the individual an isolated UCAM that does not comprise a vein or an artery, a cell with metabolic activity, active HIV-1, active HIV-2, active HTLV-1, active hepatitis B, active hepatitis C, active West Nile Virus, active cytomegalovirus, active human transmissible spongiform encephalopathy, or active Treponema pallidum.